247 related articles for article (PubMed ID: 23820334)
1. Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.
Uchida T; Suzuki T; Sakurai H; Tsutsumi C; Den R; Mimura M; Uchida H
Int Clin Psychopharmacol; 2013 Sep; 28(5):261-6. PubMed ID: 23820334
[TBL] [Abstract][Full Text] [Related]
2. Depot fluphenazine decanoate and enanthate for schizophrenia.
David A; Adams CE; Eisenbruch M; Quraishi S; Rathbone J
Cochrane Database Syst Rev; 2005 Jan; (1):CD000307. PubMed ID: 15674872
[TBL] [Abstract][Full Text] [Related]
3. Bromperidol decanoate (depot) for schizophrenia.
Purgato M; Adams CE
Cochrane Database Syst Rev; 2011 Sep; (9):CD001719. PubMed ID: 21901678
[TBL] [Abstract][Full Text] [Related]
4. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Citrome L; Jaffe A; Levine J
Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
[TBL] [Abstract][Full Text] [Related]
5. Depot bromperidol decanoate for schizophrenia.
Wong D; Adams CE; David A; Quraishi SN
Cochrane Database Syst Rev; 2004; (3):CD001719. PubMed ID: 15266450
[TBL] [Abstract][Full Text] [Related]
6. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
Chouinard G; Annable L; Campbell W
J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
[TBL] [Abstract][Full Text] [Related]
7. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics.
Turner M; Eerdekens E; Jacko M; Eerdekens M
Int Clin Psychopharmacol; 2004 Jul; 19(4):241-9. PubMed ID: 15201572
[TBL] [Abstract][Full Text] [Related]
8. Rehospitalization risk with second-generation and depot antipsychotics.
Conley RR; Kelly DL; Love RC; McMahon RP
Ann Clin Psychiatry; 2003 Mar; 15(1):23-31. PubMed ID: 12839430
[TBL] [Abstract][Full Text] [Related]
9. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
Roose K
Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
[TBL] [Abstract][Full Text] [Related]
10. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
Kissling W; Möller HJ; Walter K; Wittmann B; Krueger R; Trenk D
Pharmacopsychiatry; 1985 May; 18(3):240-5. PubMed ID: 4011672
[TBL] [Abstract][Full Text] [Related]
11. Depot fluphenazine for schizophrenia.
Adams CE; Eisenbruch M
Cochrane Database Syst Rev; 2000; (2):CD000307. PubMed ID: 10796340
[TBL] [Abstract][Full Text] [Related]
12. Adherence to depot versus oral antipsychotic medication in schizophrenic patients during the long-term therapy.
Stanković Z; Ille T
Vojnosanit Pregl; 2013 Mar; 70(3):267-73. PubMed ID: 23607237
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia.
Shi L; Ascher-Svanum H; Zhu B; Faries D; Montgomery W; Marder SR
Psychiatr Serv; 2007 Apr; 58(4):482-8. PubMed ID: 17412849
[TBL] [Abstract][Full Text] [Related]
14. Fluphenazine enanthate in the outpatient treatment of late paraphrenia.
Raskind M; Alvarez C; Herlin S
J Am Geriatr Soc; 1979 Oct; 27(10):459-63. PubMed ID: 469146
[TBL] [Abstract][Full Text] [Related]
15. [Clinical and economic approach to evaluation of the effectiveness of moditen-depot and haloperidol decanoate in the maintenance therapy of attack-like schizophrenia].
Ushakov IuV; Kravchenko NE; Kopeĭko GI; Kalugina LI; Mirzoian MG
Zh Nevropatol Psikhiatr Im S S Korsakova; 1990; 90(7):99-104. PubMed ID: 1979463
[TBL] [Abstract][Full Text] [Related]
16. Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone.
Moore DB; Kelly DL; Sherr JD; Love RC; Conley RR
Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S17-9. PubMed ID: 9872689
[No Abstract] [Full Text] [Related]
17. Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia.
Zhu B; Ascher-Svanum H; Shi L; Faries D; Montgomery W; Marder SR
Psychiatr Serv; 2008 Mar; 59(3):315-7. PubMed ID: 18308914
[TBL] [Abstract][Full Text] [Related]
18. Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate.
Cookson JC; Kennedy NM; Gribbon D
Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():41-51. PubMed ID: 3549879
[TBL] [Abstract][Full Text] [Related]
19. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
20. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice.
Altamura AC; Sassella F; Santini A; Montresor C; Fumagalli S; Mundo E
Drugs; 2003; 63(5):493-512. PubMed ID: 12600227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
